CIK 0001108205 · Non-accelerated filer<br>Smaller reporting company
CURIS INC
Sign in to watch- Ticker
- CRIS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043505116
- Phone
- 617-503-6500
- Business address
- 128 SPRING STREET, BUILDING C, SUITE 500, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-17 | Zung Jonathan B. CDO | Grant or award · Series A Warrant (right to buy) | +66,667 | 66,667 | ||
| 2026-03-17 | Zung Jonathan B. CDO | Grant or award · Series B Warrant (right to buy) | +66,667 | 66,667 | ||
| 2026-03-17 | Zung Jonathan B. CDO | Grant or award · Series C Warrant (right to buy) | +66,667 | 66,667 | ||
| 2026-03-17 | Hamdy Ahmed MD CMO | Grant or award · Series B Convertible Preferred Stock | +50 | 50 | ||
| 2026-03-17 | Hamdy Ahmed MD CMO | Grant or award · Series A Warrant (right to buy) | +66,667 | 66,667 | ||
| 2026-03-17 | Hamdy Ahmed MD CMO | Grant or award · Series B Warrant (right to buy) | +66,667 | 66,667 | ||
| 2026-03-17 | Hamdy Ahmed MD CMO | Grant or award · Series C Warrant (right to buy) | +66,667 | 66,667 | ||
| 2026-03-17 | Duvall Diantha CFO | Grant or award · Series B Convertible Preferred Stock | +50 | 50 | ||
| 2026-03-17 | Duvall Diantha CFO | Grant or award · Series A Warrant (right to buy) | +66,666 | 66,666 | ||
| 2026-03-17 | Duvall Diantha CFO | Grant or award · Series B Warrant (right to buy) | +66,666 | 66,666 | ||
| 2026-03-17 | Duvall Diantha CFO | Grant or award · Series C Warrant (right to buy) | +66,666 | 66,666 | ||
| 2026-03-17 | Dentzer James E President & CEO | Grant or award · Series B Convertible Preferred Stock | +100 | 100 | ||
| 2026-03-17 | Dentzer James E President & CEO | Grant or award · Series A Warrant (right to buy) | +133,333 | 133,333 | ||
| 2026-03-17 | Dentzer James E President & CEO | Grant or award · Series B Warrant (right to buy) | +133,333 | 133,333 | ||
| 2026-03-17 | Dentzer James E President & CEO | Grant or award · Series C Warrant (right to buy) | +133,333 | 133,333 | ||
| 2026-03-17 | Rubin Marc Director | Grant or award · Series B Convertible Preferred Stock | +20 | 20 | ||
| 2026-03-17 | Rubin Marc Director | Grant or award · Series A Warrant (right to buy) | +26,667 | 26,667 | ||
| 2026-03-17 | Rubin Marc Director | Grant or award · Series B Warrant (right to buy) | +26,667 | 26,667 | ||
| 2026-03-17 | Rubin Marc Director | Grant or award · Series C Warrant (right to buy) | +26,667 | 26,667 | ||
| 2025-05-20 | Dentzer James E President & CEO | Grant or award · Employee stock option (right to buy) | +360,000 | $3.13 | $1.1M | 360,000 |
Page 2 of 17 · 326 trades